Clinical Feature of Men Who Benefit from Dose Escalation of Naftopidil for Lower Urinary Tract Symptoms: A Prospective Study
Objectives. To examine the feature of men who benefit from dose escalation of naftopidil for lower urinary tract symptoms (LUTSs). Methods. Based on the IPSS, men reporting LUTS were prospectively studied using 50 mg/day of naftopidil for the first 4 weeks; satisfied patients continued its 50 mg/day...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2011-01-01
|
| Series: | Advances in Urology |
| Online Access: | http://dx.doi.org/10.1155/2011/804583 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832555878896631808 |
|---|---|
| author | Takaki Mizusawa Noboru Hara Kenji Obara Etsuko Isahaya Yuki Nakagawa Kota Takahashi |
| author_facet | Takaki Mizusawa Noboru Hara Kenji Obara Etsuko Isahaya Yuki Nakagawa Kota Takahashi |
| author_sort | Takaki Mizusawa |
| collection | DOAJ |
| description | Objectives. To examine the feature of men who benefit from dose escalation of naftopidil for lower urinary tract symptoms (LUTSs). Methods. Based on the IPSS, men reporting LUTS were prospectively studied using 50 mg/day of naftopidil for the first 4 weeks; satisfied patients continued its 50 mg/day (𝑛=11), and those reporting unsatisfactory improvement received its 75 mg/day (𝑛=35) for the next 4 weeks. Results. The 75 mg group showed improvement in the total IPSS and QOL score in a dose-dependent manner (at 4 weeks: 𝑃<.001, at 4 weeks versus 8 weeks: 𝑃<.05). In the 50 mg group, both scores reduced at 4 weeks, thereafter unchanged. The baseline slow stream score alone was higher in the 75 mg group (𝑃=.013). The rate of change in the QOL score during the initial 4 weeks (ΔQOL) and Δnocturia was smaller in the 75 mg group (𝑃<.05). Conclusions. Men with high slow stream score and unsatisfactory improvement in nocturia may benefit from dose escalation of naftopidil. |
| format | Article |
| id | doaj-art-bc98164dc4724209b6f80b52390ede42 |
| institution | Kabale University |
| issn | 1687-6369 1687-6377 |
| language | English |
| publishDate | 2011-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Advances in Urology |
| spelling | doaj-art-bc98164dc4724209b6f80b52390ede422025-02-03T05:47:01ZengWileyAdvances in Urology1687-63691687-63772011-01-01201110.1155/2011/804583804583Clinical Feature of Men Who Benefit from Dose Escalation of Naftopidil for Lower Urinary Tract Symptoms: A Prospective StudyTakaki Mizusawa0Noboru Hara1Kenji Obara2Etsuko Isahaya3Yuki Nakagawa4Kota Takahashi5Division of Urology, Department of Regenerative and Transplant Medicine, Graduate School of Medical and Dental Sciences, Niigata University, Asahimachi 1, Niigata 951-8510, JapanDivision of Urology, Department of Regenerative and Transplant Medicine, Graduate School of Medical and Dental Sciences, Niigata University, Asahimachi 1, Niigata 951-8510, JapanDivision of Urology, Department of Regenerative and Transplant Medicine, Graduate School of Medical and Dental Sciences, Niigata University, Asahimachi 1, Niigata 951-8510, JapanDivision of Urology, Department of Regenerative and Transplant Medicine, Graduate School of Medical and Dental Sciences, Niigata University, Asahimachi 1, Niigata 951-8510, JapanDivision of Urology, Department of Regenerative and Transplant Medicine, Graduate School of Medical and Dental Sciences, Niigata University, Asahimachi 1, Niigata 951-8510, JapanDivision of Urology, Department of Regenerative and Transplant Medicine, Graduate School of Medical and Dental Sciences, Niigata University, Asahimachi 1, Niigata 951-8510, JapanObjectives. To examine the feature of men who benefit from dose escalation of naftopidil for lower urinary tract symptoms (LUTSs). Methods. Based on the IPSS, men reporting LUTS were prospectively studied using 50 mg/day of naftopidil for the first 4 weeks; satisfied patients continued its 50 mg/day (𝑛=11), and those reporting unsatisfactory improvement received its 75 mg/day (𝑛=35) for the next 4 weeks. Results. The 75 mg group showed improvement in the total IPSS and QOL score in a dose-dependent manner (at 4 weeks: 𝑃<.001, at 4 weeks versus 8 weeks: 𝑃<.05). In the 50 mg group, both scores reduced at 4 weeks, thereafter unchanged. The baseline slow stream score alone was higher in the 75 mg group (𝑃=.013). The rate of change in the QOL score during the initial 4 weeks (ΔQOL) and Δnocturia was smaller in the 75 mg group (𝑃<.05). Conclusions. Men with high slow stream score and unsatisfactory improvement in nocturia may benefit from dose escalation of naftopidil.http://dx.doi.org/10.1155/2011/804583 |
| spellingShingle | Takaki Mizusawa Noboru Hara Kenji Obara Etsuko Isahaya Yuki Nakagawa Kota Takahashi Clinical Feature of Men Who Benefit from Dose Escalation of Naftopidil for Lower Urinary Tract Symptoms: A Prospective Study Advances in Urology |
| title | Clinical Feature of Men Who Benefit from Dose Escalation of Naftopidil for Lower Urinary Tract Symptoms: A Prospective Study |
| title_full | Clinical Feature of Men Who Benefit from Dose Escalation of Naftopidil for Lower Urinary Tract Symptoms: A Prospective Study |
| title_fullStr | Clinical Feature of Men Who Benefit from Dose Escalation of Naftopidil for Lower Urinary Tract Symptoms: A Prospective Study |
| title_full_unstemmed | Clinical Feature of Men Who Benefit from Dose Escalation of Naftopidil for Lower Urinary Tract Symptoms: A Prospective Study |
| title_short | Clinical Feature of Men Who Benefit from Dose Escalation of Naftopidil for Lower Urinary Tract Symptoms: A Prospective Study |
| title_sort | clinical feature of men who benefit from dose escalation of naftopidil for lower urinary tract symptoms a prospective study |
| url | http://dx.doi.org/10.1155/2011/804583 |
| work_keys_str_mv | AT takakimizusawa clinicalfeatureofmenwhobenefitfromdoseescalationofnaftopidilforlowerurinarytractsymptomsaprospectivestudy AT noboruhara clinicalfeatureofmenwhobenefitfromdoseescalationofnaftopidilforlowerurinarytractsymptomsaprospectivestudy AT kenjiobara clinicalfeatureofmenwhobenefitfromdoseescalationofnaftopidilforlowerurinarytractsymptomsaprospectivestudy AT etsukoisahaya clinicalfeatureofmenwhobenefitfromdoseescalationofnaftopidilforlowerurinarytractsymptomsaprospectivestudy AT yukinakagawa clinicalfeatureofmenwhobenefitfromdoseescalationofnaftopidilforlowerurinarytractsymptomsaprospectivestudy AT kotatakahashi clinicalfeatureofmenwhobenefitfromdoseescalationofnaftopidilforlowerurinarytractsymptomsaprospectivestudy |